Show simple item record

AuthorElewa H.
AuthorEl-Makaty H.
AuthorAli Z.
Available date2020-01-01T10:25:01Z
Publication Date2018
Publication NameJournal of Cardiovascular Pharmacology and Therapeutics
AbstractIntroduction: Over the past few years, direct oral anticoagulants (DOACs) have been gradually replacing warfarin. Inappropriate prescribing of DOACs in real-life practice settings can affect their perceived safety and efficacy, especially with the lack of a surrogate marker for guidance. Objectives: To describe the appropriateness of DOACs prescribing, compare dabigatran to rivaroxaban in terms of inappropriate prescribing, and determine other factors associated with inappropriate DOACs use. Methods: In this cross-sectional retrospective study, 5-year DOAC prescriptions data were extracted. Appropriateness was evaluated based on approved dosing and indications in Canada and the United States. Descriptive and inferential statistics were performed using SPSS. Results: From 2011 to 2015, there were 1049 DOACs prescriptions, among which 572 (54.5%) were for dabigatran and 477(45.5%) were for rivaroxaban. The DOACs were prescribed for inappropriate indication in 35 (3.3%) patients, while inappropriate dosing was found in 352 (33.6%) prescriptions. There were significantly more inappropriate dabigatran prescriptions compared to rivaroxaban both in terms of indication (4.7% vs 1.7%, P =.004) and dosing (50.9% vs 12.8%, P <.001). Logistic regression analysis confirmed that dabigatran prescribing was the only factor associated with inappropriate indications (odds ratio [OR] = 2.9, 95% confidence interval [CI]: 1.3-6.5). Factors associated with inappropriate dosing included dabigatran prescriptions (OR = 7.6, 95% CI: 5.5-10.5) and poor renal function (OR = 14.6, 95% CI: 3.6-58.4). Conclusion: Direct oral anticoagulants have been gradually replacing warfarin in Qatar; however, they are not always prescribed appropriately especially in patients on dabigatran and those with renal impairment. Educating health-care practitioners is necessary. Future studies comparing the clinical safety and effectiveness of the DOACs especially when used at an inappropriate dose are also warranted. - 2017, - The Author(s) 2017.
SponsorThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Qatar University internal grant # (QUST-CPH-SPRING-15/16-9).
PublisherSAGE Publications Ltd
dc.source Scopus
Subjectdirect oral anticoagulants
TitleAppropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience
Issue Number2
Volume Number23

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record